PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

Phase 2 Not yet recruiting 60 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Novartis Pharmaceuticals · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6 months) is (1) safe and effective compared to standard of care alone, and (2) can reduce the side effects caused by long-term (24 months) ADT in men with high risk localized prostate cancer.

Timeline

Start: 2026-07
Primary completion: 2032-07
Completion: 2033-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	177Lu-PSMA-617	Other / unclassified	—	Intravenous

Indications

No indication recorded.